Spruce Biosciences transfers CRHX-101 program to Adrenyx Biosciences

• Spruce Biosciences separated its CRHX-101 program into newly formed, wholly owned subsidiary Adrenyx Biosciences, focused on endocrinology.
• A planned pro rata distribution of all Adrenyx shares would create two independent public companies in the first half of 2027.
• Adrenyx issued $5 million in secured convertible promissory notes on November 6, 2026, under an agreement permitting up to $10 million.
• A planned private placement includes up to $50 million from the notes investor, inclusive of its note funding.
• Adrenyx will develop CRHX-101 for classic CAH; its parent will retain its neurological focus, led by TA-ERT for MPS IIIB.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109728260) on November 09, 2026, and is solely responsible for the information contained therein.